Mrs Anna Chérouvrier Hansson
Invest in Skåne is the official inward investment agency for Skåne. Our mission is to promote international investment and trade in Southern Sweden. We help with partnerships and assist businesses in getting access to new markets. We pursue our mission by facilitating contacts with international corporations, and by promoting the Life Science expertise already present in the region.
With several years of experience in business development and life science, our team will assist your company in a simple 4-step process:
- We define your business and partnership goals and determine what technology, products and competencies you are looking for.
- We identify local companies, academic institutions and CMOs/CROs in your field highlighting potential business opportunities.
- We arrange a visiting programme where you can initiate explorative discussions with prospective business partners.
- We will support your efforts to successfully complete your partnership or investment project.
Invest in Skåne
Head of Business Development Life Science
Mr Jan-Erik Collin
Chundsell Medicals AB was founded in 2007 based on the need for a more specific system, the Prostatype test system, to diagnose prostate cancer and to predict the survival prognosis for patients. The test also distinguishes between the aggressive and non-aggressive tumors.
The business idea is to market and sell to the global market a complete diagnostic system consisting of reagents, an instrument platform and evaluation software. We strive to develop and produce frontline product solutions designed for optimal user compliance as well as fulfillment of the highest quality demands. Our product system will meet an urgent medical need and will have a positive impact on the overall health economy as well as preserve the quality of life for thousands of men each year.
The patent pending Prostatype test is based on real- time-quantitative-PCR (qPCR) where we analyze the expression of a set of genes in cancer stem cells. The expression of these genes can with high statistical significance identify patients with aggressive tumors (20%) from the ones with non-aggressive tumors (80%). The results are based on a clinical endpoint study where patients have been followed-up on for more than 20 years. The results have shown that the gene signatures can classify different tumor types, indicate overall and cancer specific survival and serve as a guide to the urologist to choose therapy like prostate surgery, radiation, hormone treatment or watchful waiting.
